1. Ludwig H, Miguel JS, Dimopoulos MA, et al: International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014; 28: 981–992
2. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65:175-181, 2000
3. Murphy PT, Baldeo C, O'Kelly P, et al. Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma. Br J Haematol. 2014;165(6):890-891.
4. Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant. 2010;25(2):419-426
5. Thaw SS, Sahmoun A, Schwartz GG, et al. Serum calcium, tumor size, and hormone receptor status in women with untreated breast cancer. Cancer Biol Ther 2012;13:467-71.
6. Schwartz GG, Tretli S, Vos L, et al. Prediagnostic serum calcium and albumin and ovarian cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort. Cancer Epidemiol 2017;49:
225-30.
7. Schwartz GG, and Skinner HG. A prospective study of total and ionized serum calcium and time to fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2012;21:1768-73
8. Lin Y, Zhou J, Cao L, et al. Serum calcium is a novel parameter to assess metabolic syndrome in endometrial carcinoma. J Gynecol Oncol 2019;30:e12
9. Dimitrios Christoulas, Evangelos Terpos, Meletios A Dimopoulos: Pathogenesis and management of myeloma bone disease. Expert Rev Hematol . 2009 Aug;2(4):385-98.
10. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev. 2008;34(1):92-101
11. KC Abbott, LY Agodoa: Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001 Sep;56(3):207-10.
12. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma: Pathogenesis and prognostic implications. Arch Intern Med 150:1693-1695, 1990
13. Flora Zagouri, Efstathios Kastritis, Athanasios Zomas, Evangelos Terpos, Eirini Katodritou, Argiris Symeonidis, Sosana Delimpasi, Anastasia Pouli, Theodoros P Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel anti-myeloma therapies. Eur J Haematol. 2017 Nov;99(5):409-414
14. Augustson BM, Begum G, Dunn JA, et al:Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23:9219-9226,2005
15. Costa LJ, Gonsalves WI, Kumar SK: Early mortality in multiple myeloma. Leukemia 29: 1616-1618, 2015
16. Kristinsson SY, Anderson WF, Landgren O: Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28:1346-1348, 2014
17. Ronald S Go ,Adam C Bartley,Cynthia S Crowson, Nilay D Shah, et al: Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma. J Clin Oncol. 2017 Feb 20;35(6):598-604.
18. Bushinsky DA, Monk RD. Electrolyte quintet: calcium. Lancet 1998;352:306–311
19. Nerea Becerra-Tomás,Ramón Estruch,Mònica Bulló, Rosa Casas, Andrés Díaz-López, Josep Basora .Increased Serum Calcium Levels and Risk of Type 2 Diabetes in Individuals at High Cardiovascular Risk. Diabetes Care 2014;37:3084–3091
20. Calvi LM, Bushinsky DA. When is it appropriate to order an ionized calcium? J Am Soc Nephrol 2008;19:1257–1260
21. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538-48
22. Masson I, Flamant M, Maillard N, et al: MDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients. Transplantation 95:1211-1217, 2013
23. Inker LA, Schmid CH, Tighiouart H, et al: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20-29,2012
24. Yanyu Lyu, MD, PhD; Prakesh S. Shah, MD, MSc; Xiang Y. Ye, MSc; Ruth Warre, PhD; Bruno Piedboeuf, MD Association Between Admission Temperature and Mortality and Major Morbidity in Preterm Infants Born at Fewer Than 33 Weeks’ Gestation JAMA Pediatr. 2015;169(4):e150277
25. Liu S, Wang X, Lu Y, Li T, Gong Z, Sheng T, et al. The effects of intraoperative cryoprecipitate transfusion on acute renal failure following orthotropic liver transplantation. Hepatol Int. 2013;7:901–9
26. Dimopoulos MA, Kastritis E, Rosinol L, et al: Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485-1493, 2008
27. Barlogie B, Dixon D: Renal failurein multiple myeloma: Pathogenesis and prognostic implications. Arch Intern Med 150:1693-1695, 1990
28. Riccardi A, Gobbi PG, Ucci G, et al: Changing clinical presentation of multiple myeloma. Eur J Cancer 27:1401-1405, 1991
29. Hutchison CA, Batuman V, Behrens J, et al: The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 8:43-51, 2012
30. Dimopoulos MA, Delimpasi S, Katodritou E,et al: Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25:195-200, 2014
31. Uttervall K, Duru AD, Lund J, et al: The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One 9:e101819, 2014
32. Khan R, Apewokin S, Grazziutti M, et al: Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia 29:1195-1201, 2015